Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
Are there certain patient characteristics that drive you to recommend intralesional 5-FU or MTX for a large SCC on the back?
Related Questions
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
Would you favor radiation or immune modulating treatment like imiquimod to treat an uncomplicated basal cell carcinoma on the nose in an elderly patient for whom you'd like to avoid surgery?
Do computerized mole-mapping tools play a role in your clinical practice?
What’s your approach to treating multiple facial BCCs in gorlin syndrome?
Would you offer adjuvant immunotherapy in an elderly patient with stage IIB desmoplastic melanoma post resection with underlying autoimmune disease?
What patient characteristics or clinical scenarios guide the decision in performing slow Mohs procedures?
In patients with multiple basal cell carcinoma lesions on vismodegib, would you hold vismodegib while delivering radiation therapy to one locally advanced BCC lesion that was not amenable to surgery?
How do you approach patients with advanced resectable basal cell carcinoma for possible use of hedgehog inhibitors?
Have you considered intralesional cempilumab for locally advanced NMSC/KCs prior to surgery?
How frequently do you recommend skin cancer screens in your patients with kidney transplants who are on immunosuppression?
